{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:40:51Z","timestamp":1781307651990,"version":"3.54.1"},"reference-count":124,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Viral infections or persistent alcohol or drug abuse, together with intrinsic factors, lead to hepatitis, which often ends in the development of liver cirrhosis or hepatocellular carcinoma (HCC). With this review, we describe inflammatory liver diseases, such as acute liver failure, virus-induced hepatitis, alcoholic- and non-alcoholic steatohepatitis, and autoimmune hepatitis, and highlight their driving mechanisms. These include external factors such as alcohol misuse, viral infection and supernutrition, as well as intrinsic parameters such as genetic disposition and failure, in immune tolerance. Additionally, we describe what is known about the translational machinery within all these diseases. Distinct eukaryotic translation initiation factors (eIFs) with specific functional roles and aberrant expression in HCC are reported. Many alterations to the translational machinery are already triggered in the precancerous lesions described in this review, highlighting mTOR pathway proteins and eIFs to emphasize their putative clinical relevance. Here, we identified a lack of knowledge regarding the roles of single eIF proteins. A closer investigation will help to understand and treat HCC as well as the antecedent diseases.<\/jats:p>","DOI":"10.3390\/cells11030533","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:35:17Z","timestamp":1643974517000},"page":"533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Translational Bridge between Inflammation and Hepatocarcinogenesis"],"prefix":"10.3390","volume":"11","author":[{"given":"Sabine","family":"Gufler","sequence":"first","affiliation":[{"name":"Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Seeboeck","sequence":"additional","affiliation":[{"name":"Clinical Institute of Pathology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, 3100 St. Poelten, Austria"},{"name":"Department Life Sciences, IMC University of Applied Sciences Krems, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-3400","authenticated-orcid":false,"given":"Christoph","family":"Schatz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Haybaeck","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria"},{"name":"Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, 8010 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/15384101.2015.1038685","article-title":"Autophagy and apoptosis in liver injury","volume":"14","author":"Wang","year":"2015","journal-title":"Cell Cycle"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","article-title":"Acute liver failure","volume":"394","author":"Stravitz","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S2468-1253(20)30084-4","article-title":"COVID-19 and the liver: Little cause for concern","volume":"5","author":"Bangash","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2012.03.017","article-title":"Liver transplantation for acute liver failure in Europe: Outcomes over 20 years from the ELTR database","volume":"57","author":"Germani","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cld.2018.06.002","article-title":"Hepatitis B and C","volume":"22","author":"Mysore","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e037473","DOI":"10.1136\/bmjopen-2020-037473","article-title":"Systematic review of the global epidemiology of viral-induced acute liver failure","volume":"10","author":"Patterson","year":"2020","journal-title":"BMJ Open"},{"key":"ref_8","unstructured":"Trautwein, C.K.A. (2014). Liver Immunology: Principles and Practice, Springer Science+Business Media."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2010.11.005","article-title":"Endoplasmic reticulum stress in liver disease","volume":"54","author":"Malhi","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bpg.2008.11.002","article-title":"Chronic viral hepatitis as a public health issue in the world","volume":"22","author":"Lavanchy","year":"2008","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cobb, B.R., and Valsamakis, A. (2016). Chronic Hepatitis B, C, and D. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.DMIH2-0025-2015"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1586\/14787210.2016.1174066","article-title":"Chronic hepatitis B and C infection in the United States: A review of current guidelines, disease burden and cost effectiveness of screening","volume":"14","author":"Sarpel","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global Elimination of Chronic Hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Herrscher, C., Roingeard, P., and Blanchard, E. (2020). Hepatitis B Virus Entry into Cells. Cells, 9.","DOI":"10.3390\/cells9061486"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.3748\/wjg.v23.i20.3589","article-title":"Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review","volume":"23","author":"Lin","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jam.14727","article-title":"Hepatitis A infections from food","volume":"129","author":"Randazzo","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2017.08.034","article-title":"Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention","volume":"68","author":"Lemon","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","volume":"17","author":"Revill","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mam.2007.09.015","article-title":"Personalized therapy in chronic viral hepatitis","volume":"29","author":"Brunetto","year":"2008","journal-title":"Mol. Aspects Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2893.2012.01591.x","article-title":"Hepatitis C virus and the brain","volume":"19","author":"Fletcher","year":"2012","journal-title":"J. Viral. Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2741\/3685","article-title":"Chronic viral hepatitis: Epidemiology, molecular biology, and antiviral therapy","volume":"16","author":"Gonzalez","year":"2011","journal-title":"Front. Biosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coviro.2021.05.002","article-title":"Structural perspectives on HCV humoral immune evasion mechanisms","volume":"49","author":"Sevvana","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1128\/JVI.78.10.5170-5183.2004","article-title":"Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants","volume":"78","author":"Forton","year":"2004","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.3748\/wjg.v26.i22.2931","article-title":"Liver-related effects of chronic hepatitis C antiviral treatment","volume":"26","author":"Laursen","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges","volume":"17","author":"Zeng","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2893.2009.01154.x","article-title":"Quality of life considerations for patients with chronic hepatitis C","volume":"16","author":"Foster","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1136\/gutjnl-2014-308971","article-title":"Host cell mTORC1 is required for HCV RNA replication","volume":"65","author":"Costa","year":"2016","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1074\/jbc.M115.664995","article-title":"Interferon \u03b3 (IFN\u03b3) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses","volume":"291","author":"Kroczynska","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.jhep.2013.07.033","article-title":"Interferon-stimulated genes and their role in controlling hepatitis C virus","volume":"59","author":"Metz","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/emboj.2011.146","article-title":"eIF2A mediates translation of hepatitis C viral mRNA under stress conditions","volume":"30","author":"Kim","year":"2011","journal-title":"Embo J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39477","DOI":"10.1074\/jbc.M305038200","article-title":"Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2.GTP.Met-tRNAi","volume":"278","author":"Hui","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"34064","DOI":"10.1074\/jbc.M605771200","article-title":"Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56","volume":"281","author":"Terenzi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jare.2019.03.009","article-title":"A review on hepatitis D: From virology to new therapies","volume":"17","author":"Mentha","year":"2019","journal-title":"J. Adv. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2019.09.012","article-title":"Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection","volume":"54","author":"Brancaccio","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, Z., and Urban, S. (2020). Interplay between Hepatitis D Virus and the Interferon Response. Viruses, 12.","DOI":"10.3390\/v12111334"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.admecli.2003.11.001","article-title":"Chronic viral hepatitis","volume":"15","author":"Suskind","year":"2004","journal-title":"Adolesc. Med. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jvh.12156","article-title":"Chronic hepatitis E: A review of the literature","volume":"21","author":"Fujiwara","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","article-title":"Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment","volume":"26","author":"Aslan","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1099\/jgv.0.001229","article-title":"Hepatitis E virus polymerase binds to IFIT1 to protect the viral RNA from IFIT1-mediated translation inhibition","volume":"100","author":"Pingale","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yin, X., and Feng, Z. (2019). Hepatitis E Virus Entry. Viruses, 11.","DOI":"10.3390\/v11100883"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2174\/1381612824666180410091511","article-title":"Cytochrome P450s and Alcoholic Liver Disease","volume":"24","author":"Lu","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3748\/wjg.v24.i26.2785","article-title":"Liver transplantation and alcoholic liver disease: History, controversies, and considerations","volume":"24","author":"Marroni","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5009\/gnl16477","article-title":"Pathophysiology and Management of Alcoholic Liver Disease: Update 2016","volume":"11","author":"Stickel","year":"2017","journal-title":"Gut Liver"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"s54","DOI":"10.7861\/clinmedicine.18-2-s54","article-title":"Genetics of alcoholic liver disease and non-alcoholic steatohepatitis","volume":"18","author":"Scott","year":"2018","journal-title":"Clin. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cld.2018.09.006","article-title":"Pathogenesis of Alcoholic Liver Disease","volume":"23","author":"Kourkoumpetis","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"G589","DOI":"10.1152\/ajpgi.00245.2020","article-title":"Effects of dietary components on intestinal permeability in health and disease","volume":"319","author":"Khoshbin","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Plaza-D\u00edaz, J., Sol\u00eds-Urra, P., Rodr\u00edguez-Rodr\u00edguez, F., Olivares-Arancibia, J., Navarro-Oliveros, M., Abad\u00eda-Molina, F., and \u00c1lvarez-Mercado, A.I. (2020). The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218351"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2018.12.003","article-title":"Fibrosis and alcohol-related liver disease","volume":"70","author":"Lackner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.27732","article-title":"DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma","volume":"61","author":"Villanueva","year":"2015","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/MEG.0000000000001235","article-title":"Nonalcoholic fatty liver disease: Current concepts, epidemiology and management strategies","volume":"30","author":"Tomic","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0973-6883(12)60102-9","article-title":"Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease","volume":"2","author":"Mishra","year":"2012","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: An expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: A population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1665-2681(19)31922-2","article-title":"Prevalence of non-alcoholic fatty liver disease: Population based study","volume":"6","author":"Amarapurkar","year":"2007","journal-title":"Ann. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00535-003-1178-8","article-title":"Increase in the prevalence of fatty liver in Japan over the past 12 years: Analysis of clinical background","volume":"38","author":"Kojima","year":"2003","journal-title":"J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"Schwimmer","year":"2005","journal-title":"Hepatology"},{"key":"ref_72","first-page":"384","article-title":"Non-alcoholic Fatty Liver Disease: A Clinical Update","volume":"5","author":"Pappachan","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1503\/cmaj.045232","article-title":"Nonalcoholic fatty liver disease","volume":"172","author":"Adams","year":"2005","journal-title":"CMAJ"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin. Med."},{"key":"ref_75","first-page":"275","article-title":"Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations","volume":"24","author":"Silverman","year":"1989","journal-title":"Pathol. Ann."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"20462","DOI":"10.1074\/jbc.R114.576355","article-title":"Pathway-selective insulin resistance and metabolic disease: The importance of nutrient flux","volume":"289","author":"Otero","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10839","DOI":"10.18632\/aging.102488","article-title":"HIF-2\u03b1 upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway","volume":"11","author":"Chen","year":"2019","journal-title":"Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","article-title":"Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis","volume":"67","author":"Marengo","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2019.00082","article-title":"The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity","volume":"10","author":"Weyler","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: An emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474124.1.1.113","article-title":"Autoimmune hepatitis. Part A: Pathogenesis","volume":"1","author":"Czaja","year":"2007","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3350\/cmh.2020.0189","article-title":"Recent updates on the management of autoimmune hepatitis","volume":"27","author":"Komori","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: Key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Vergani","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Lee, G.R. (2018). The Balance of Th17 versus Treg Cells in Autoimmunity. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030730"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1081-1206(10)62426-X","article-title":"T-cell subsets (Th1 versus Th2)","volume":"85","author":"Romagnani","year":"2000","journal-title":"Ann. Allergy Asthma. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pathol-020117-043534","article-title":"Cellular and Molecular Mechanisms of Autoimmune Hepatitis","volume":"13","author":"Webb","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40266-018-0556-0","article-title":"Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management","volume":"35","author":"Rizvi","year":"2018","journal-title":"Drugs Aging"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"185","DOI":"10.32074\/1591-951X-241","article-title":"Pathology of autoimmune hepatitis","volume":"113","author":"Covelli","year":"2021","journal-title":"Pathologica"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00795-020-00255-5","article-title":"Differences in autoimmune hepatitis based on inflammation localization","volume":"54","author":"Takahashi","year":"2021","journal-title":"Med. Mol. Morphol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.humpath.2018.07.014","article-title":"Histologic features of autoimmune hepatitis: A critical appraisal","volume":"82","author":"Gurung","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000449340","article-title":"Molecular Pathogenesis of Hepatocellular Carcinoma","volume":"5","author":"Ho","year":"2016","journal-title":"Liver Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1038\/s41388-018-0152-0","article-title":"Beyond molecular tumor heterogeneity: Protein synthesis takes control","volume":"37","author":"Ramon","year":"2018","journal-title":"Oncogene"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ferr\u00edn, G., Guerrero, M., Amado, V., Rodr\u00edguez-Per\u00e1lvarez, M., and De la Mata, M. (2020). Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041266"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Sun, E.J., Wankell, M., Palamuthusingam, P., McFarlane, C., and Hebbard, L. (2021). Targeting the PI3K\/Akt\/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111639"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in molecular classification and precision oncology in hepatocellular carcinoma","volume":"72","author":"Rebouissou","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000333254","article-title":"Signaling pathways in hepatocellular carcinoma","volume":"81","author":"Sia","year":"2011","journal-title":"Oncology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Fu, W., and Hall, M.N. (2020). Regulation of mTORC2 Signaling. Genes, 11.","DOI":"10.3390\/genes11091045"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.molcel.2005.11.016","article-title":"eIF3: A connecTOR of S6K1 to the translation preinitiation complex","volume":"20","author":"Peterson","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/ncb3225","article-title":"mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype","volume":"17","author":"Herranz","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e45947","DOI":"10.15252\/embr.201845947","article-title":"Translation acrobatics: How cancer cells exploit alternate modes of translational initiation","volume":"19","author":"Sriram","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fonc.2016.00128","article-title":"Cap-Independent Translational Control of Carcinogenesis","volume":"6","author":"Walters","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molcel.2017.10.002","article-title":"m(6)A Facilitates eIF4F-Independent mRNA Translation","volume":"68","author":"Coots","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/15476286.2017.1353863","article-title":"Does eIF3 promote reinitiation after translation of short upstream ORFs also in mammalian cells?","volume":"14","author":"Mohammad","year":"2017","journal-title":"RNA Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/B978-0-12-386497-0.00002-5","article-title":"Termination and post-termination events in eukaryotic translation","volume":"86","author":"Jackson","year":"2012","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70 S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.2147\/DDDT.S255582","article-title":"Translational Regulation in Hepatocellular Carcinogenesis","volume":"15","author":"Schatz","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"188441","DOI":"10.1016\/j.bbcan.2020.188441","article-title":"Immunotherapy for advanced hepatocellular carcinoma, where are we?","volume":"1874","author":"Zhang","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12964-020-00607-9","article-title":"Eukaryotic translation initiation factors as promising targets in cancer therapy","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/cei.13496","article-title":"Rapamycin-based graft-versus-host disease prophylaxis increases the immunosuppressivity of myeloid-derived suppressor cells without affecting T cells and anti-tumor cytotoxicity","volume":"202","author":"Scheurer","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","article-title":"The ClinicalTrials.gov results database\u2014Update and key issues","volume":"364","author":"Zarin","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: Its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transp. Proc."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"26032","DOI":"10.18632\/oncotarget.25430","article-title":"CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128","volume":"9","author":"Badawi","year":"2018","journal-title":"Oncotarget"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:46Z","timestamp":1760134426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":124,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11030533"],"URL":"https:\/\/doi.org\/10.3390\/cells11030533","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}